世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
光線性角化症治療薬 - 世界市場シェア・ランキング、全体売上高・需要予測 2024-2030Medications for Actinic Keratosis - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030 光線性角化症治療薬の世界市場は、2023年には100万米ドル規模と推定され、2024〜2030年の予測期間中のCAGRは%で、2030年には100万米ドルに再調整されると予測されている。 世界の医薬品市場は2022年に1,475億米... もっと見る
※当ページの内容はウェブ更新時の情報です。 
サマリー光線性角化症治療薬の世界市場は、2023年には100万米ドル規模と推定され、2024〜2030年の予測期間中のCAGRは%で、2030年には100万米ドルに再調整されると予測されている。世界の医薬品市場は2022年に1,475億米ドルで、今後6年間のCAGRは5%で成長する。医薬品市場には化学医薬品と生物学的製剤が含まれる。生物製剤は2022年に3810億米ドルになると予想されている。これに対し、化学医薬品市場は2018年の1,050億米ドルから2022年には1,090億米ドルに増加すると推定されている。医薬品市場の要因としては、医療需要の増加、技術の進歩、慢性疾患の有病率の上昇、医薬品製造分野の開発に対する民間＆政府機関からの資金提供の増加、医薬品の研究開発活動の活発化などが挙げられる。しかし、厳しい規制、研究開発費の高騰、特許切れといった課題にも直面している。企業は、市場での競争力を維持し、必要としている患者に確実に製品を届けるために、継続的に技術革新を行い、こうした課題に適応していく必要がある。さらに、COVID-19の大流行はワクチン開発とサプライチェーン管理の重要性を浮き彫りにし、製薬企業が新たな公衆衛生のニーズに機敏に対応する必要性をさらに強調している。 レポートの範囲 本レポートは、光線性角化症治療薬の世界市場について、地域別・国別、タイプ別、用途別の分析とともに、総売上高、主要企業の市場シェア、ランキングを中心に包括的に紹介することを目的としています。 光線性角化症治療薬の市場規模、推計、予測は、2023年を基準年とし、2019年から2030年までの期間の履歴データと予測データを売上高（百万ドル）で提供しています。定量的および定性的な分析により、読者がビジネス/成長戦略を策定し、市場競争状況を評価し、現在の市場における自社のポジションを分析し、光線性角化症治療薬に関する情報に基づいたビジネス上の意思決定を行うのに役立ちます。 市場区分 企業別 サン・ファーマシューティカルズ バイオフロンテラ ネスレ ボシュ・ヘルス・カンパニーズ ノバルティスAG グラクソ・スミスクライン plc. アルミラルLLC レオ・ファーマ サイファー・ファーマシューティカルズ ピエール・ファーブル製薬株式会社 タイプ別セグメント フルリジン イミキモド ジクロフェナク その他 用途別セグメント 病院 指定薬局 その他 地域別 北米 米国 カナダ 欧州 ドイツ フランス 英国 イタリア ロシア アジア太平洋 中国 日本 韓国 中国 台湾 東南アジア インド ラテンアメリカ メキシコ ブラジル アルゼンチン 中東・アフリカ トルコ サウジアラビア アラブ首長国連邦 各章の概要 第1章： レポートのスコープ、世界の総市場規模を紹介。本章ではまた、市場ダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界のメーカーが直面する課題とリスク、業界の関連政策の分析を提供します。 第2章： 光線性角化症治療薬メーカーの競争環境、収益市場シェア、最新の開発計画、合併・買収情報などを詳細に分析します。 第3章：タイプ別に様々な市場セグメントの分析を提供し、各市場セグメントの市場規模と発展可能性を網羅し、読者が様々な市場セグメントにおけるブルーオーシャン市場を見つけるのに役立つ。 第4章：読者が異なる川下市場のブルーオーシャン市場を見つけるのを助けるために、各市場セグメントの市場規模と発展の可能性をカバーする、アプリケーション別の様々な市場セグメントの分析を提供します。 第5章：地域レベルでの光線性角化症治療薬の収益。各地域の市場規模と発展可能性を定量的に分析し、世界各国の市場発展、将来発展見込み、市場空間、市場規模を紹介しています。 第6章：国別の光線性角化症治療薬の収益。各国・地域のタイプ別、用途別のシグメイトデータを提供。 第7章：主要企業のプロフィールを提供し、製品収益、粗利益率、製品紹介、最近の開発など、市場における主要企業の基本的な状況を詳細に紹介する。 第8章：産業の上流と下流を含む産業チェーンの分析。 第9章：結論 目次1 Market Overview1.1 Medications for Actinic Keratosis Product Introduction 1.2 Global Medications for Actinic Keratosis Market Size Forecast 1.3 Medications for Actinic Keratosis Market Trends & Drivers 1.3.1 Medications for Actinic Keratosis Industry Trends 1.3.2 Medications for Actinic Keratosis Market Drivers & Opportunity 1.3.3 Medications for Actinic Keratosis Market Challenges 1.3.4 Medications for Actinic Keratosis Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Medications for Actinic Keratosis Players Revenue Ranking (2023) 2.2 Global Medications for Actinic Keratosis Revenue by Company (2019-2024) 2.3 Key Companies Medications for Actinic Keratosis Manufacturing Base Distribution and Headquarters 2.4 Key Companies Medications for Actinic Keratosis Product Offered 2.5 Key Companies Time to Begin Mass Production of Medications for Actinic Keratosis 2.6 Medications for Actinic Keratosis Market Competitive Analysis 2.6.1 Medications for Actinic Keratosis Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Medications for Actinic Keratosis Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Medications for Actinic Keratosis as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Fluridine 3.1.2 Imiquimod 3.1.3 Diclofenac 3.1.4 Others 3.2 Global Medications for Actinic Keratosis Sales Value by Type 3.2.1 Global Medications for Actinic Keratosis Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Medications for Actinic Keratosis Sales Value, by Type (2019-2030) 3.2.3 Global Medications for Actinic Keratosis Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Designated Pharmacy 4.1.3 Others 4.2 Global Medications for Actinic Keratosis Sales Value by Application 4.2.1 Global Medications for Actinic Keratosis Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Medications for Actinic Keratosis Sales Value, by Application (2019-2030) 4.2.3 Global Medications for Actinic Keratosis Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Medications for Actinic Keratosis Sales Value by Region 5.1.1 Global Medications for Actinic Keratosis Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Medications for Actinic Keratosis Sales Value by Region (2019-2024) 5.1.3 Global Medications for Actinic Keratosis Sales Value by Region (2025-2030) 5.1.4 Global Medications for Actinic Keratosis Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Medications for Actinic Keratosis Sales Value, 2019-2030 5.2.2 North America Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Medications for Actinic Keratosis Sales Value, 2019-2030 5.3.2 Europe Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Medications for Actinic Keratosis Sales Value, 2019-2030 5.4.2 Asia Pacific Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Medications for Actinic Keratosis Sales Value, 2019-2030 5.5.2 South America Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Medications for Actinic Keratosis Sales Value, 2019-2030 5.6.2 Middle East & Africa Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Medications for Actinic Keratosis Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Medications for Actinic Keratosis Sales Value 6.3 United States 6.3.1 United States Medications for Actinic Keratosis Sales Value, 2019-2030 6.3.2 United States Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Medications for Actinic Keratosis Sales Value, 2019-2030 6.4.2 Europe Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Medications for Actinic Keratosis Sales Value, 2019-2030 6.5.2 China Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.5.3 China Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Medications for Actinic Keratosis Sales Value, 2019-2030 6.6.2 Japan Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Medications for Actinic Keratosis Sales Value, 2019-2030 6.7.2 South Korea Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Medications for Actinic Keratosis Sales Value, 2019-2030 6.8.2 Southeast Asia Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Medications for Actinic Keratosis Sales Value, 2019-2030 6.9.2 India Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.9.3 India Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Sun Pharmaceutical lndustries Ltd. 7.1.1 Sun Pharmaceutical lndustries Ltd. Profile 7.1.2 Sun Pharmaceutical lndustries Ltd. Main Business 7.1.3 Sun Pharmaceutical lndustries Ltd. Medications for Actinic Keratosis Products, Services and Solutions 7.1.4 Sun Pharmaceutical lndustries Ltd. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.1.5 Sun Pharmaceutical lndustries Ltd. Recent Developments 7.2 Biofrontera 7.2.1 Biofrontera Profile 7.2.2 Biofrontera Main Business 7.2.3 Biofrontera Medications for Actinic Keratosis Products, Services and Solutions 7.2.4 Biofrontera Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.2.5 Biofrontera Recent Developments 7.3 Nestle sA 7.3.1 Nestle sA Profile 7.3.2 Nestle sA Main Business 7.3.3 Nestle sA Medications for Actinic Keratosis Products, Services and Solutions 7.3.4 Nestle sA Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.3.5 Bausch Health Companies Inc. Recent Developments 7.4 Bausch Health Companies Inc. 7.4.1 Bausch Health Companies Inc. Profile 7.4.2 Bausch Health Companies Inc. Main Business 7.4.3 Bausch Health Companies Inc. Medications for Actinic Keratosis Products, Services and Solutions 7.4.4 Bausch Health Companies Inc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.4.5 Bausch Health Companies Inc. Recent Developments 7.5 Novartis AG 7.5.1 Novartis AG Profile 7.5.2 Novartis AG Main Business 7.5.3 Novartis AG Medications for Actinic Keratosis Products, Services and Solutions 7.5.4 Novartis AG Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.5.5 Novartis AG Recent Developments 7.6 GlaxoSmithKline plc. 7.6.1 GlaxoSmithKline plc. Profile 7.6.2 GlaxoSmithKline plc. Main Business 7.6.3 GlaxoSmithKline plc. Medications for Actinic Keratosis Products, Services and Solutions 7.6.4 GlaxoSmithKline plc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.6.5 GlaxoSmithKline plc. Recent Developments 7.7 Almirall,LLC 7.7.1 Almirall,LLC Profile 7.7.2 Almirall,LLC Main Business 7.7.3 Almirall,LLC Medications for Actinic Keratosis Products, Services and Solutions 7.7.4 Almirall,LLC Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.7.5 Almirall,LLC Recent Developments 7.8 LEO Pharma Inc. 7.8.1 LEO Pharma Inc. Profile 7.8.2 LEO Pharma Inc. Main Business 7.8.3 LEO Pharma Inc. Medications for Actinic Keratosis Products, Services and Solutions 7.8.4 LEO Pharma Inc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.8.5 LEO Pharma Inc. Recent Developments 7.9 Cipher Pharmaceuticals Inc. 7.9.1 Cipher Pharmaceuticals Inc. Profile 7.9.2 Cipher Pharmaceuticals Inc. Main Business 7.9.3 Cipher Pharmaceuticals Inc. Medications for Actinic Keratosis Products, Services and Solutions 7.9.4 Cipher Pharmaceuticals Inc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.9.5 Cipher Pharmaceuticals Inc. Recent Developments 7.10 Pierre Fabre Pharmaceuticals, Inc. 7.10.1 Pierre Fabre Pharmaceuticals, Inc. Profile 7.10.2 Pierre Fabre Pharmaceuticals, Inc. Main Business 7.10.3 Pierre Fabre Pharmaceuticals, Inc. Medications for Actinic Keratosis Products, Services and Solutions 7.10.4 Pierre Fabre Pharmaceuticals, Inc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.10.5 Pierre Fabre Pharmaceuticals, Inc. Recent Developments 8 Industry Chain Analysis 8.1 Medications for Actinic Keratosis Industrial Chain 8.2 Medications for Actinic Keratosis Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Medications for Actinic Keratosis Sales Model 8.5.2 Sales Channel 8.5.3 Medications for Actinic Keratosis Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
SummaryThe global market for Medications for Actinic Keratosis was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030. Table of Contents1 Market Overview1.1 Medications for Actinic Keratosis Product Introduction 1.2 Global Medications for Actinic Keratosis Market Size Forecast 1.3 Medications for Actinic Keratosis Market Trends & Drivers 1.3.1 Medications for Actinic Keratosis Industry Trends 1.3.2 Medications for Actinic Keratosis Market Drivers & Opportunity 1.3.3 Medications for Actinic Keratosis Market Challenges 1.3.4 Medications for Actinic Keratosis Market Restraints 1.4 Assumptions and Limitations 1.5 Study Objectives 1.6 Years Considered 2 Competitive Analysis by Company 2.1 Global Medications for Actinic Keratosis Players Revenue Ranking (2023) 2.2 Global Medications for Actinic Keratosis Revenue by Company (2019-2024) 2.3 Key Companies Medications for Actinic Keratosis Manufacturing Base Distribution and Headquarters 2.4 Key Companies Medications for Actinic Keratosis Product Offered 2.5 Key Companies Time to Begin Mass Production of Medications for Actinic Keratosis 2.6 Medications for Actinic Keratosis Market Competitive Analysis 2.6.1 Medications for Actinic Keratosis Market Concentration Rate (2019-2024) 2.6.2 Global 5 and 10 Largest Companies by Medications for Actinic Keratosis Revenue in 2023 2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Medications for Actinic Keratosis as of 2023) 2.7 Mergers & Acquisitions, Expansion 3 Segmentation by Type 3.1 Introduction by Type 3.1.1 Fluridine 3.1.2 Imiquimod 3.1.3 Diclofenac 3.1.4 Others 3.2 Global Medications for Actinic Keratosis Sales Value by Type 3.2.1 Global Medications for Actinic Keratosis Sales Value by Type (2019 VS 2023 VS 2030) 3.2.2 Global Medications for Actinic Keratosis Sales Value, by Type (2019-2030) 3.2.3 Global Medications for Actinic Keratosis Sales Value, by Type (%) (2019-2030) 4 Segmentation by Application 4.1 Introduction by Application 4.1.1 Hospital 4.1.2 Designated Pharmacy 4.1.3 Others 4.2 Global Medications for Actinic Keratosis Sales Value by Application 4.2.1 Global Medications for Actinic Keratosis Sales Value by Application (2019 VS 2023 VS 2030) 4.2.2 Global Medications for Actinic Keratosis Sales Value, by Application (2019-2030) 4.2.3 Global Medications for Actinic Keratosis Sales Value, by Application (%) (2019-2030) 5 Segmentation by Region 5.1 Global Medications for Actinic Keratosis Sales Value by Region 5.1.1 Global Medications for Actinic Keratosis Sales Value by Region: 2019 VS 2023 VS 2030 5.1.2 Global Medications for Actinic Keratosis Sales Value by Region (2019-2024) 5.1.3 Global Medications for Actinic Keratosis Sales Value by Region (2025-2030) 5.1.4 Global Medications for Actinic Keratosis Sales Value by Region (%), (2019-2030) 5.2 North America 5.2.1 North America Medications for Actinic Keratosis Sales Value, 2019-2030 5.2.2 North America Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 5.3 Europe 5.3.1 Europe Medications for Actinic Keratosis Sales Value, 2019-2030 5.3.2 Europe Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 5.4 Asia Pacific 5.4.1 Asia Pacific Medications for Actinic Keratosis Sales Value, 2019-2030 5.4.2 Asia Pacific Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 5.5 South America 5.5.1 South America Medications for Actinic Keratosis Sales Value, 2019-2030 5.5.2 South America Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 5.6 Middle East & Africa 5.6.1 Middle East & Africa Medications for Actinic Keratosis Sales Value, 2019-2030 5.6.2 Middle East & Africa Medications for Actinic Keratosis Sales Value by Country (%), 2023 VS 2030 6 Segmentation by Key Countries/Regions 6.1 Key Countries/Regions Medications for Actinic Keratosis Sales Value Growth Trends, 2019 VS 2023 VS 2030 6.2 Key Countries/Regions Medications for Actinic Keratosis Sales Value 6.3 United States 6.3.1 United States Medications for Actinic Keratosis Sales Value, 2019-2030 6.3.2 United States Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.3.3 United States Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.4 Europe 6.4.1 Europe Medications for Actinic Keratosis Sales Value, 2019-2030 6.4.2 Europe Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.4.3 Europe Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.5 China 6.5.1 China Medications for Actinic Keratosis Sales Value, 2019-2030 6.5.2 China Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.5.3 China Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.6 Japan 6.6.1 Japan Medications for Actinic Keratosis Sales Value, 2019-2030 6.6.2 Japan Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.6.3 Japan Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.7 South Korea 6.7.1 South Korea Medications for Actinic Keratosis Sales Value, 2019-2030 6.7.2 South Korea Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.7.3 South Korea Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.8 Southeast Asia 6.8.1 Southeast Asia Medications for Actinic Keratosis Sales Value, 2019-2030 6.8.2 Southeast Asia Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.8.3 Southeast Asia Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 6.9 India 6.9.1 India Medications for Actinic Keratosis Sales Value, 2019-2030 6.9.2 India Medications for Actinic Keratosis Sales Value by Type (%), 2023 VS 2030 6.9.3 India Medications for Actinic Keratosis Sales Value by Application, 2023 VS 2030 7 Company Profiles 7.1 Sun Pharmaceutical lndustries Ltd. 7.1.1 Sun Pharmaceutical lndustries Ltd. Profile 7.1.2 Sun Pharmaceutical lndustries Ltd. Main Business 7.1.3 Sun Pharmaceutical lndustries Ltd. Medications for Actinic Keratosis Products, Services and Solutions 7.1.4 Sun Pharmaceutical lndustries Ltd. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.1.5 Sun Pharmaceutical lndustries Ltd. Recent Developments 7.2 Biofrontera 7.2.1 Biofrontera Profile 7.2.2 Biofrontera Main Business 7.2.3 Biofrontera Medications for Actinic Keratosis Products, Services and Solutions 7.2.4 Biofrontera Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.2.5 Biofrontera Recent Developments 7.3 Nestle sA 7.3.1 Nestle sA Profile 7.3.2 Nestle sA Main Business 7.3.3 Nestle sA Medications for Actinic Keratosis Products, Services and Solutions 7.3.4 Nestle sA Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.3.5 Bausch Health Companies Inc. Recent Developments 7.4 Bausch Health Companies Inc. 7.4.1 Bausch Health Companies Inc. Profile 7.4.2 Bausch Health Companies Inc. Main Business 7.4.3 Bausch Health Companies Inc. Medications for Actinic Keratosis Products, Services and Solutions 7.4.4 Bausch Health Companies Inc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.4.5 Bausch Health Companies Inc. Recent Developments 7.5 Novartis AG 7.5.1 Novartis AG Profile 7.5.2 Novartis AG Main Business 7.5.3 Novartis AG Medications for Actinic Keratosis Products, Services and Solutions 7.5.4 Novartis AG Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.5.5 Novartis AG Recent Developments 7.6 GlaxoSmithKline plc. 7.6.1 GlaxoSmithKline plc. Profile 7.6.2 GlaxoSmithKline plc. Main Business 7.6.3 GlaxoSmithKline plc. Medications for Actinic Keratosis Products, Services and Solutions 7.6.4 GlaxoSmithKline plc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.6.5 GlaxoSmithKline plc. Recent Developments 7.7 Almirall,LLC 7.7.1 Almirall,LLC Profile 7.7.2 Almirall,LLC Main Business 7.7.3 Almirall,LLC Medications for Actinic Keratosis Products, Services and Solutions 7.7.4 Almirall,LLC Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.7.5 Almirall,LLC Recent Developments 7.8 LEO Pharma Inc. 7.8.1 LEO Pharma Inc. Profile 7.8.2 LEO Pharma Inc. Main Business 7.8.3 LEO Pharma Inc. Medications for Actinic Keratosis Products, Services and Solutions 7.8.4 LEO Pharma Inc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.8.5 LEO Pharma Inc. Recent Developments 7.9 Cipher Pharmaceuticals Inc. 7.9.1 Cipher Pharmaceuticals Inc. Profile 7.9.2 Cipher Pharmaceuticals Inc. Main Business 7.9.3 Cipher Pharmaceuticals Inc. Medications for Actinic Keratosis Products, Services and Solutions 7.9.4 Cipher Pharmaceuticals Inc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.9.5 Cipher Pharmaceuticals Inc. Recent Developments 7.10 Pierre Fabre Pharmaceuticals, Inc. 7.10.1 Pierre Fabre Pharmaceuticals, Inc. Profile 7.10.2 Pierre Fabre Pharmaceuticals, Inc. Main Business 7.10.3 Pierre Fabre Pharmaceuticals, Inc. Medications for Actinic Keratosis Products, Services and Solutions 7.10.4 Pierre Fabre Pharmaceuticals, Inc. Medications for Actinic Keratosis Revenue (US$ Million) & (2019-2024) 7.10.5 Pierre Fabre Pharmaceuticals, Inc. Recent Developments 8 Industry Chain Analysis 8.1 Medications for Actinic Keratosis Industrial Chain 8.2 Medications for Actinic Keratosis Upstream Analysis 8.2.1 Key Raw Materials 8.2.2 Raw Materials Key Suppliers 8.2.3 Manufacturing Cost Structure 8.3 Midstream Analysis 8.4 Downstream Analysis (Customers Analysis) 8.5 Sales Model and Sales Channels 8.5.1 Medications for Actinic Keratosis Sales Model 8.5.2 Sales Channel 8.5.3 Medications for Actinic Keratosis Distributors 9 Research Findings and Conclusion 10 Appendix 10.1 Research Methodology 10.1.1 Methodology/Research Approach 10.1.2 Data Source 10.2 Author Details 10.3 Disclaimer
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療/ヘルスケア）の最新刊レポート
QYResearch社の医薬・ヘルスケア分野での最新刊レポート本レポートと同じKEY WORD（）の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|